Home > Products > Consucon
Share Print This Page

Consucon (Gliclazide)
Therapeutic Group: Anti Diabetic » Oral hypoglycaemic

Consucon: Each tablet contains Gliclazide BP 80 mg.

Consucon MR: Each modified release tablet contains Gliclazide BP 30 mg.

Consucon (Gliclazide) is a second generation sulfonylurea drug that has hypoglycaemic and potentially useful haemobiological properties. It stimulates the release of insulin from pancreatic beta-cells by facilitating Ca+2 transport across the beta-cell membranes and decreases hepatic glucose output.
Consucon and Consucon MR is indicated for the treatment of type 2 diabetes mellitus.
Dosage & Administration
Consucon: The usual initial dose is 40 to 80 mg daily. The dose can be increased upto 320 mg daily in divided doses when needed. The drug should be taken before meal.

Consucon MR: The usual daily dosage is 1 to 4 tablets per day as a single dose. It is recommended that the drug should be taken at breakfast time. It is preferable to take this drug before breakfast in order to avoid or to minimize the possible onset of digestive disorders.
Side Effects
There may be hypoglycaemia in concurrent conditions such as hepatic and renal disease, malnutrition, alcohol intoxication. Sometimes headache, gastrointestinal upsets, nausea, dizziness, skin reactions including rash, pruritus, erythema may occur.
Gliclazide should be used carefully in patients with hepatic impairment. If there is definite hepatic disease then gliclazide should not be used. Consucon (Gliclazide) can be used safely in patients with renal insufficiency as it is extensively metabolized. Consucon has less sudden hypoglycaemic episode than other sulfonylurea group of drugs.
Gliclazide should not be used in -
* Juvenile-onset (type - I) diabetes
* Diabetes associated with Ketosis
* Diabetic patients undergoing surgery, after severe injury or during infection
* Patients having hypersensitivity for sulfonylurea group of drugs
* Pregnant women and breast-feeding mother
* Hepatic insufficiency
Use in Pregnancy & Lactation
Pregnant Women: Gliclazide should not be used in pregnant women although animal studies of Gliclazide have not shown any teratogenic effect.
Nursing Mothers: This drug is contraindicated when breast feeding.
In accidental overdose, at first gastric lavage should be done and at the same time the hypoglycaemia should be corrected. In severe cases I/V infusion of 5% glucose should be started immediately with frequent monitoring of blood glucose and potassium level.
Store in a cool and dry place, below 30 °C and away from light.
Commercial Packaging
Consucon: Each box containing 5 blister strips of 10 tablets.
Consucon MR: Each box containing 5 blister strips of 10 tablets.
Products from the same therapeutic group
Anti Diabetic
Insulin and Its Preparations
Human Insulin (rDNA)
Insulin Glargine (rDNA) Injection
Oral hypoglycaemic
Linagliptin INN
Linatab M
Linagliptin + Metformin HCl Tablet
Glimepiride Tablet
Losucon M 1/500 SR
Glimepiride 1 mg and Metformin HCL 500 mg Tablet
Metformin Hydrochloride
Repaglinide 0.5,1,2 mg Raditab
Pioglitazone tablet
Sitagliptin Phosphate INN
Sitagil M ER
Sitagliptin Phosphate Monohydrate INN 64.25 mg eq. to Sitagliptin 50mg & Metformin HCl BP 500 mg